Heron's pain candidate meets in Phase IIb ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) reported that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. Heron intends to submit an NDA to FDA next half for the candidate. FDA also

Read the full 370 word article

User Sign In